Patents by Inventor Augustine Osuma

Augustine Osuma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PRIMARY CARBOXAMIDES AS BTK INHIBITORS
    Publication number: 20210179556
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 17, 2021
    Inventors: Dominique Bonafoux, Heather Michele Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep Kaur Somal, Jennifer Van Camp, Stacy Anne Van Epps, Anil Vasudevan, Grier Allan Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu
  • PRIMARY CARBOXAMIDES AS BTK INHIBITORS
    Publication number: 20190284135
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 19, 2019
    Inventors: Dominique Bonafoux, Heather Michele Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep Kaur Somal, Jennifer Van Camp, Stacy Anne Van Epps, Anil Vasudevan, Grier Allan Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu
  • HETEROCYCLIC KINASE INHIBITORS
    Publication number: 20190135836
    Abstract: This invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers, and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 21, 2018
    Publication date: May 9, 2019
    Inventors: Michael Friedman, Phil Cox, Kristine E. Frank, Michael Z. Hoemann, Augustine Osuma, Noel S. Wilson, Xiangdong Xu, Kevin Cusack, Raymond Huntley, J. Martin Herold
  • Heterocyclic kinase inhibitors
    Patent number: 10280184
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: May 7, 2019
    Assignee: AbbVie Inc.
    Inventors: Michael M. Friedman, Philip Cox, Kristine E. Frank, Michael Z. Hoemann, Augustine Osuma, Noel S. Wilson, Xiangdong Xu, Kevin Cusack, Raymond Huntley, J. Martin Herold
  • Indazolones as modulators of TNF signaling
    Patent number: 10273238
    Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: April 30, 2019
    Assignee: AbbVie Inc.
    Inventors: Eric C. Breinlinger, Andrew Burchat, Justin Dietrich, Michael Friedman, David Ihle, David Kinsman, Kelly Mullen, Augustine Osuma, Anil Vasudevan, Noel S. Wilson
  • Indazolones as modulators of tnf signaling
    Patent number: 10160748
    Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: December 25, 2018
    Assignee: AbbVie Inc.
    Inventors: Maria Argiriadi, Eric Breinlinger, Justin D. Dietrich, Michael Friedman, David Ihle, Michael Morytko, Kelly Mullen, Augustine Osuma, Gloria Y. LoSchiavo, Noel S. Wilson
  • INDAZOLONES AS MODULATORS OF TNF SIGNALING
    Publication number: 20180086737
    Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: August 7, 2017
    Publication date: March 29, 2018
    Inventors: Maria Argiriadi, Eric Breinlinger, Justin D. Dietrich, Michael Friedman, David Ihle, Michael Morytko, Kelly Mullen, Augustine Osuma, Gloria Y. LoSchiavo, Noel S. Wilson
  • Indazolones as modulators of TNF signaling
    Patent number: 9879016
    Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 30, 2018
    Assignee: AbbVie Inc.
    Inventors: Eric Breinlinger, Andrew Burchat, Justin Dietrich, Michael Friedman, David Ihle, David Kinsman, Kelly Mullen, Augustine Osuma, Anil Vasudevan, Noel Wilson
  • Tricyclic modulators of TNF signaling
    Patent number: 9856253
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 2, 2018
    Assignee: AbbVie, Inc.
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton Longenecker, Augustine Osuma, Ann Marie Rowley, Anil Vasudevan, Noel Wilson
  • PRIMARY CARBOXAMIDES AS BTK INHIBITORS
    Publication number: 20170174624
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: January 5, 2017
    Publication date: June 22, 2017
    Applicant: AbbVie Inc.
    Inventors: Dominique Bonafoux, Heather M. Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep K. Somal, Jennifer Van Camp, Stacy A. Van Epps, Anil Vasudevan, Grier A. Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu
  • HETEROCYCLIC KINASE INHIBITORS
    Publication number: 20170114077
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 16, 2015
    Publication date: April 27, 2017
    Inventors: Michael M. FRIDEMAN, Philip COX, Kristine E. FRANK, Michael Z. HOEMANN, Augustine OSUMA, Noel S. WILSON, Xiangdong XU, Kevin CUSACK, Raymond HUNTLEY, J. Martin HEROLD
  • Primary carboxamides as BTK inhibitors
    Patent number: 9567339
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: February 14, 2017
    Assignee: AbbVie Inc.
    Inventors: Dominique Bonafoux, Heather M. Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep K. Somal, Jennifer Van Camp, Stacy A. Van Epps, Anil Vasudevan, Grier A. Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu
  • INDAZOLONES AS MODULATORS OF TNF SIGNALING
    Publication number: 20160304526
    Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Eric Breinlinger, Andrew Burchat, Justin Dietrich, Michael Friedman, David Ihle, David Kinsman, Kelly Mullen, Augustine Osuma, Anil Vasudevan, Noel Wilson
  • TRICYCLIC MODULATORS OF TNF SIGNALING
    Publication number: 20160304517
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Eric C. Breinlinger, Phil B. Cox, Jerome Daanen, Justin Dietrich, Stevan Djuric, Amanda W. Dombrowski, Kristine E. Frank, Michael M. Friedman, Arthur Gomtsyan, Huan-Qui Li, Kenton Longenecker, Augustine Osuma, Ann Marie Rowley, Robert Schmidt, Anil Vasudevan, Noel Wilson
  • INDAZOLONES AS MODULATORS OF TNF SIGNALING
    Publication number: 20160304496
    Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Maria Argiriadi, Eric Breinlinger, Justin D. Dietrich, Michael Friedman, David Ihle, Michael Morytko, Kelly Mullen, Augustine Osuma, Glora Y. Lo Schiavo, Noel S. Wilson
  • PRIMARY CARBOXAMIDES AS BTK INHIBITORS
    Publication number: 20150005279
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: June 26, 2014
    Publication date: January 1, 2015
    Applicant: ABBVIE INC.
    Inventors: Dominique Bonafoux, Heather M. Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep K. Somal, Jennifer Van Camp, Stacy A. Van Epps, Anil Vasudevan, Grier A. Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu
  • Process for the synthesis of N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids
    Publication number: 20070219394
    Abstract: The invention claimed herein provides a process to oxidize N-(5-alkoxy-2-methyl-4-nitrophenyl)acetamides to N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids using potassium permanganate in the presence of magnesium sulfate in aqueous sulfolane or aqueous pyridine.
    Type: Application
    Filed: May 18, 2007
    Publication date: September 20, 2007
    Applicant: Wyeth
    Inventors: Scott Duncan, Augustine Osuma, Sylvain Daigneault, Michel Bernatchez
  • AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN
    Publication number: 20070129550
    Abstract: Certain ?-amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel are disclosed. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders. Also disclosed are methods of making the ?-amino acids.
    Type: Application
    Filed: December 7, 2006
    Publication date: June 7, 2007
    Applicant: WANER-LAMBERT COMPANY LLC
    Inventors: Peter Blazecka, Joseph Bozelak, Norman Colbry, Timothy Curran, Annise Goodman, Kevin Henegar, Garrett Hoge, Paul Johnson, Augustine Osuma, Mark Plummer, Jacob Schwarz, Derek Vrieze, Ji Zhang
  • Amino acids with affinity for the alpha2delta-protein
    Publication number: 20050101643
    Abstract: Certain ?-amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel are disclosed. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders. Also disclosed are methods of making the ?-amino acids.
    Type: Application
    Filed: September 24, 2004
    Publication date: May 12, 2005
    Inventors: Peter Blazecka, Joseph Bozelak, Norman Colbry, Timothy Curran, Annise Goodman, Kevin Henegar, Garrett Hoge, Paul Johnson, Augustine Osuma, Mark Plummer, Jacob Schwarz, Derek Vrieze, Ji Zhang
  • Process for the synthesis of nacyl-2-amino-4-alkoxy-5-nitrobenzoic acids
    Publication number: 20050085662
    Abstract: The invention claimed herein provides a process to oxidize N-(5-alkoxy-2-methyl-4-nitrophenyl)acetamides to N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids using potassium permanganate in the presence of magnesium sulfate in aqueous sulfolane or aqueous pyridine.
    Type: Application
    Filed: February 5, 2003
    Publication date: April 21, 2005
    Applicant: Wyeth
    Inventors: Scott Duncan, Augustine Osuma, Sylvain Daigneault, Michel Bernatchez